X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6303) 6303
Book Review (1872) 1872
Publication (295) 295
Book Chapter (75) 75
Conference Proceeding (55) 55
Book / eBook (13) 13
Dissertation (5) 5
Magazine Article (5) 5
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4415) 4415
antithrombotic therapy (3862) 3862
humans (3832) 3832
male (1887) 1887
female (1737) 1737
atrial fibrillation (1533) 1533
anticoagulants (1433) 1433
cardiac & cardiovascular systems (1433) 1433
aged (1426) 1426
warfarin (1414) 1414
anticoagulants - therapeutic use (1403) 1403
risk factors (1283) 1283
stroke (1262) 1262
peripheral vascular disease (1176) 1176
middle aged (1071) 1071
prevention (1060) 1060
hematology (1053) 1053
aspirin (963) 963
thrombosis (934) 934
anticoagulation (848) 848
management (789) 789
atrial fibrillation - drug therapy (779) 779
treatment outcome (761) 761
risk (754) 754
thromboembolism (748) 748
anticoagulants - adverse effects (732) 732
stroke - prevention & control (730) 730
anticoagulants - administration & dosage (728) 728
aged, 80 and over (724) 724
pharmacology & pharmacy (715) 715
venous thromboembolism (687) 687
fibrinolytic agents - therapeutic use (670) 670
medicine, general & internal (670) 670
animals (657) 657
atrial fibrillation - complications (656) 656
atrial-fibrillation (652) 652
abridged index medicus (635) 635
stroke prevention (580) 580
administration, oral (559) 559
risk-factors (554) 554
hemorrhage - chemically induced (525) 525
platelet aggregation inhibitors - therapeutic use (520) 520
medicine & public health (489) 489
care and treatment (488) 488
molecular-weight heparin (486) 486
warfarin - therapeutic use (483) 483
adult (476) 476
retrospective studies (466) 466
antithrombotic (465) 465
stroke - etiology (461) 461
mortality (455) 455
risk assessment (450) 450
surgery (450) 450
drug therapy (446) 446
cardiology (426) 426
clopidogrel (417) 417
analysis (413) 413
bleeding (413) 413
heparin (399) 399
dabigatran (389) 389
deep-vein thrombosis (387) 387
antiplatelet therapy (385) 385
percutaneous coronary intervention (377) 377
oral anticoagulation (364) 364
rivaroxaban (347) 347
therapy (347) 347
guidelines (346) 346
oral anticoagulants (343) 343
hemorrhage (339) 339
myocardial-infarction (339) 339
clinical neurology (334) 334
thromboembolism - prevention & control (328) 328
thrombosis - drug therapy (324) 324
aspirin - therapeutic use (319) 319
cardiac arrhythmia (317) 317
metaanalysis (316) 316
time factors (316) 316
internal medicine (315) 315
ed american-college (314) 314
acute coronary syndromes (312) 312
antithrombotic agents (311) 311
acute myocardial-infarction (308) 308
antithrombotics (304) 304
fibrinolytic agents - adverse effects (303) 303
cardiovascular (296) 296
antithrombotic treatment (292) 292
incidence (290) 290
prospective studies (286) 286
practice guidelines as topic (283) 283
drug therapy, combination (282) 282
patients (280) 280
research (275) 275
unfractionated heparin (274) 274
platelet aggregation inhibitors - adverse effects (272) 272
thrombosis - prevention & control (271) 271
warfarin - adverse effects (266) 266
health aspects (265) 265
dose-response relationship, drug (260) 260
prevalence (260) 260
anticoagulant (255) 255
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5857) 5857
German (177) 177
Spanish (107) 107
French (101) 101
Japanese (57) 57
Russian (51) 51
Portuguese (20) 20
Polish (14) 14
Korean (10) 10
Czech (9) 9
Italian (9) 9
Hungarian (7) 7
Turkish (6) 6
Chinese (3) 3
Dutch (2) 2
Serbian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e326S - e350S
Background: This guideline addresses the management of patients who are receiving anticoagulant or antiplatelet therapy and require an elective surgery or... 
VITAMIN-K-ANTAGONISTS | PERCUTANEOUS CORONARY INTERVENTION | PROSTHETIC HEART-VALVES | LOW-DOSE ASPIRIN | RESPIRATORY SYSTEM | MOLECULAR-WEIGHT HEPARIN | ORAL ANTICOAGULANT-THERAPY | TRANEXAMIC ACID MOUTHWASH | NONVALVULAR ATRIAL-FIBRILLATION | INTERNATIONAL NORMALIZED RATIO | DRUG-ELUTING STENTS | CRITICAL CARE MEDICINE | Perioperative Care | United States | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Aspirin - pharmacokinetics | Angioplasty, Balloon, Coronary | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - pharmacokinetics | Postoperative Complications - drug therapy | Thrombosis - blood | Thrombosis - prevention & control | Stents | Platelet Aggregation Inhibitors - adverse effects | Drug Administration Schedule | Atrial Fibrillation - drug therapy | Heart Valve Prosthesis | Risk Factors | Atrial Fibrillation - complications | Evidence-Based Medicine | Atrial Fibrillation - blood | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Elective Surgical Procedures | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2 Suppl, pp. e691S - e736S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e669S - e690S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e419S - e496S
Background: This article addresses the treatment of VTE disease. Methods: We generated strong (Grade 1) and weak (Grade 2) recommendations based on... 
RIGHT-VENTRICULAR DYSFUNCTION | RECURRENT VENOUS THROMBOEMBOLISM | TISSUE-PLASMINOGEN-ACTIVATOR | RESPIRATORY SYSTEM | ACUTE PULMONARY-EMBOLISM | MOLECULAR-WEIGHT HEPARIN | VENA-CAVA FILTER | ORAL ANTICOAGULANT-THERAPY | INTRAVENOUS UNFRACTIONATED HEPARIN | LONG-TERM TREATMENT | DEEP-VEIN-THROMBOSIS | CRITICAL CARE MEDICINE | Venous Thrombosis - diagnosis | Pulmonary Embolism - prevention & control | United States | Humans | Venous Thrombosis - blood | Heparin, Low-Molecular-Weight - adverse effects | Hemorrhage - prevention & control | Long-Term Care | Heparin, Low-Molecular-Weight - therapeutic use | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - prevention & control | Polysaccharides - therapeutic use | Drug Administration Schedule | Venous Thrombosis - drug therapy | Administration, Oral | Risk Factors | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Pulmonary Embolism - blood | International Normalized Ratio | Diagnostic Imaging | Pulmonary Embolism - diagnosis | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e531S - e575S
Background: The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is... 
DIRECT-CURRENT CARDIOVERSION | STROKE PREVENTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | ORAL ANTICOAGULANT-THERAPY | RISK STRATIFICATION SCHEMES | MAJOR VASCULAR EVENTS | PULMONARY-VEIN ABLATION | ACUTE CORONARY SYNDROME | ECHOCARDIOGRAPHY-GUIDED CARDIOVERSION | ANTIARRHYTHMIC-DRUG THERAPY | CRITICAL CARE MEDICINE | Ticlopidine - therapeutic use | Humans | Electric Countershock | Hemorrhage - prevention & control | Dabigatran | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Stroke - prevention & control | beta-Alanine - adverse effects | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Atrial Fibrillation - blood | International Normalized Ratio | Stroke - blood | Atrial Flutter - complications | Atrial Flutter - drug therapy | Hemorrhage - chemically induced | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e737S - e801S
Background: Neonates and children differ from adults in physiology, pharmacologic responses to drugs, epidemiology, and long-term consequences of thrombosis.... 
INFERIOR VENA-CAVA | TISSUE-PLASMINOGEN-ACTIVATOR | ARTERIAL ISCHEMIC-STROKE | RESPIRATORY SYSTEM | CEREBRAL SINOVENOUS THROMBOSIS | ACUTE LYMPHOBLASTIC-LEUKEMIA | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | HEPARIN-INDUCED THROMBOCYTOPENIA | SICKLE-CELL-DISEASE | HOMOZYGOUS PROTEIN-C | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Humans | Upper Extremity Deep Vein Thrombosis - blood | Child, Preschool | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Upper Extremity Deep Vein Thrombosis - prevention & control | Hemorrhage - prevention & control | Secondary Prevention | Heparin - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Cardiac Catheterization | Vitamin K - antagonists & inhibitors | Societies, Medical | Platelet Aggregation Inhibitors - administration & dosage | Renal Veins | Thrombosis - blood | Thrombosis - prevention & control | Child | Infant, Newborn | Platelet Aggregation Inhibitors - adverse effects | Upper Extremity Deep Vein Thrombosis - drug therapy | Drug Administration Schedule | Risk Factors | Cooperative Behavior | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Interdisciplinary Communication | Thrombosis - etiology | Blood Coagulation Tests | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e576S - e600S
Background: Antithrombotic therapy in valvular disease is important to mitigate thromboembolism, but the hemorrhagic risk imposed must be considered. Methods:... 
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heart Valve Diseases - blood | Mitral Valve | Thrombosis - complications | Ductus Arteriosus, Patent - drug therapy | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Stroke - complications | Hemorrhage - prevention & control | Rheumatic Heart Disease - blood | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Ductus Arteriosus, Patent - blood | Thromboembolism - prevention & control | Aspirin - adverse effects | Heart Valve Diseases - complications | Fibrinolytic Agents - therapeutic use | Rheumatic Heart Disease - drug therapy | Rheumatic Heart Disease - complications | Aspirin - therapeutic use | Thromboembolism - drug therapy | Postoperative Complications - drug therapy | Thrombosis - blood | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Catheterization | Heart Atria | Heart Valve Prosthesis | Risk Factors | Ductus Arteriosus, Patent - complications | Combined Modality Therapy | Evidence-Based Medicine | Stroke - blood | Thromboembolism - blood | Heart Valve Diseases - drug therapy | Thrombosis - drug therapy | Hemorrhage - chemically induced | Thrombolytic Therapy - adverse effects | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e601S - e636S
Objectives: This article provides recommendations on the use of antithrombotic therapy in patients with stroke or transient ischemic attack (TIA). Methods: We... 
HIGH-RISK PATIENTS | TISSUE-PLASMINOGEN ACTIVATOR | CEREBRAL VENOUS THROMBOSIS | PATENT FORAMEN OVALE | RESPIRATORY SYSTEM | LONG-TERM SURVIVAL | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | ASPIRIN PLUS DIPYRIDAMOLE | NONVALVULAR ATRIAL-FIBRILLATION | EXTENDED-RELEASE DIPYRIDAMOLE | CRITICAL CARE MEDICINE | Recombinant Proteins - therapeutic use | United States | Humans | Heparin - therapeutic use | Tissue Plasminogen Activator - therapeutic use | Intracranial Thrombosis - prevention & control | Recombinant Proteins - adverse effects | Heparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ischemic Attack, Transient - etiology | Aspirin - therapeutic use | Intracranial Thrombosis - drug therapy | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Ischemic Attack, Transient - drug therapy | Intermittent Pneumatic Compression Devices | Intracranial Thrombosis - blood | Combined Modality Therapy | Stroke - drug therapy | Evidence-Based Medicine | Stroke - blood | Intracranial Thrombosis - etiology | Thrombolytic Therapy | Ischemic Attack, Transient - blood | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
European Heart Journal, ISSN 0195-668X, 2012, Volume 33, Issue 20, pp. 2569 - 2619
Acute coronary syndromes Ischaemic heart disease | Reperfusion therapy | Primary percutaneous coronary intervention Antithrombotic therapy | Secondary prevention | Acute myocardial infarction | ST-segment elevation | Guidelines | CARDIAC & CARDIOVASCULAR SYSTEMS | BARE-METAL STENTS | Primary percutaneous coronary intervention | AMERICAN-HEART-ASSOCIATION | PERCUTANEOUS CORONARY INTERVENTION | INTRAAORTIC BALLOON COUNTERPULSATION | Antithrombotic therapy | LEFT-VENTRICULAR DYSFUNCTION | DUAL ANTIPLATELET THERAPY | SUSPECTED CARDIOGENIC-SHOCK | IN-HOSPITAL MORTALITY | Acute coronary syndromes | Ischaemic heart disease | CONVERTING-ENZYME INHIBITOR | DRUG-ELUTING STENTS | Antifibrinolytic Agents - therapeutic use | Humans | Heart Failure - physiopathology | Hyperglycemia - complications | Anxiety - prevention & control | Long-Term Care | Hemodynamics - physiology | Cardiomyopathies - etiology | Cardiotonic Agents - therapeutic use | Heart Failure - therapy | Myocardial Infarction - therapy | Out-of-Hospital Cardiac Arrest - therapy | Percutaneous Coronary Intervention - methods | Fibrinolytic Agents - therapeutic use | Electrocardiography | Cardiac Imaging Techniques - methods | Platelet Aggregation Inhibitors - therapeutic use | Dyspnea - prevention & control | Exercise Therapy - methods | Myocardial Infarction - diagnosis | Heart Failure - complications | Coronary Artery Bypass - methods | Arrhythmias, Cardiac - therapy | Pain - prevention & control | Risk Assessment | Risk Reduction Behavior | Time-to-Treatment | Emergency Treatment - methods | Biomedical Research - trends | Arrhythmias, Cardiac - etiology | Hospitalization | Out-of-Hospital Cardiac Arrest - diagnosis | Forecasting | Myocardial Reperfusion - methods | Cardiomyopathies - therapy | Myocardial Infarction - complications | Emergency Medical Services - organization & administration | General Practice - organization & administration | Hyperglycemia - therapy | Index Medicus
Journal Article